NEW YORK, August 11, 2026, 14:03 EDT — Chipotle Mexican Grill (CMG) shares moved lower as the restaurant chain faces ongoing fallout from a nationwide jalapeño recall that is testing its efforts to restore customer traffic.
- Chipotle stock slipped 0.8% to $31.87 in late Tuesday trading.
- The FDA reports the chain has switched suppliers and has stopped serving the jalapeños in question.
- Traffic rose by 1.0% in the second quarter, but the restaurant-level margin declined by 2.2 points.
Shares of Chipotle Mexican Grill NYSE:CMG fell 0.8% to $31.87 following a jalapeño recall by Taylor Farms that heightened concerns about food safety. The FDA reported that Chipotle sourced peppers from the distributor in question. The agency also noted that Chipotle has switched suppliers and is not serving the recalled product.
The difference is significant for investors. The FDA does not view Chipotle or QDOBA as posing an active consumer risk at this time. The slight movement in shares indicates that a recall discount has not materialised so far.
As of 13:41 EDT, shares of Cava Group NYSE:CAVA slipped 1.0%. Yum! Brands NYSE:YUM declined 0.5%, and McDonald’s NYSE:MCD was down 0.4%. The three combined posted a mean loss of 0.61%. Chipotle lagged that average by 0.23 percentage point.
| Company | Price | Day move | Trailing P/E | Market value |
|---|---|---|---|---|
| Chipotle NYSE:CMG | $31.87 | down 0.84% | 28.7x | $40.8 billion |
| Cava NYSE:CAVA | $60.99 | down 0.96% | 117.2x | $7.2 billion |
| Yum! Brands NYSE:YUM | $144.65 | off 0.47% | 18.2x | $39.4 billion |
| McDonald’s NYSE:MCD | $272.59 | declined 0.41% | 22.1x | $193.8 billion |
Chipotle continues to trade at a higher valuation compared to established chains. Its price-to-earnings ratio stands at 28.7, ahead of McDonald’s at 22.1 and Yum’s at 18.2. This premium places greater emphasis on the company maintaining steady customer traffic.
The outbreak is still considered serious, though chain-level attribution is restricted. The FDA reported 345 illnesses and 36 hospitalizations spanning 27 states, with no deaths recorded. The FDA did not release figures for cases tied specifically to Chipotle.
| Outbreak measure | Latest verified figure | What changed |
|---|---|---|
| Illnesses | 345 | Involved 27 states |
| Hospitalizations | 36 | No fatalities confirmed |
| Interview evidence | 177 of 191 diners | Indicated eating at a Mexican-style restaurant |
| Chipotle action | Supplier change started July 20 | Previously affected items removed from menu |
| FDA risk view | No ongoing risk at present | Relevant to both Chipotle and QDOBA |
Taylor Fresh Foods also pulled finished products made with the peppers from the market. These products were distributed to retail centers in 26 states. The best-if-used-by dates extend through August 16. According to Taylor, there have been no reports of illnesses linked to these finished products.
Consumer hesitation poses a significant equity risk. “Consumers are likely to avoid all Taylor Farms products for a while,” Telsey Advisory Group’s Joe Feldman told Reuters. U.S. unit sales of iceberg lettuce dropped 15.3% from a year earlier during the four weeks to July 25. The previous four-week period recorded an 11.1% decrease. Reuters
Chipotle began the quarter with modest operating momentum. Second-quarter revenue increased 9.3% to $3.3 billion. Comparable sales advanced 2.2%, with a 1.2% rise in average check and a 1.0% increase in transactions.
| Operating measure | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Operating margin | 15.7% | 18.2% | -2.5 points |
| Restaurant-level margin | 25.2% | 27.4% | -2.2 points |
| Food, beverage and packaging | 29.7% of revenue | 28.9% | +0.8 point |
| Labor | 25.0% of revenue | 24.7% | +0.3 point |
| Adjusted diluted EPS | $0.33 | $0.33 | No change |
The 1.0% increase in traffic provides only a slight buffer. With check growth steady, a one-point drop in traffic would reduce the 2.2% comparable sales to about 1.2%. This represents a possible scenario, not a prediction. Chief Executive Scott Boatwright said the figures showed “the momentum we’re building.”
Analysts hold differing views regarding the extent of the recovery. The four firms listed below have recently issued price targets ranging from $36 to $45. The potential upside is measured against the $31.87 reference price.
| Research firm | Date | Rating | Price target | Upside to $31.87 |
|---|---|---|---|---|
| Argus | August 4 | Buy | $45 | 41.2% |
| Guggenheim | July 31 | Neutral | $36 | 13.0% |
| Baird | July 30 | Outperform | $44 | 38.1% |
| Stephens | July 30 | Equal weight | $40 | 25.5% |
Out of 34 analysts, the overall recommendation is Buy. The mean price target is $44.05, which is 38.2% higher than the reference price. Targets reflect analysts’ opinions and are not assurances of future returns.
The key drawback is postponed avoidance from consumers. Introduction of a new warning specific to a chain, a drop in traffic, or another surge in produce prices could undermine the argument. However, the risk would be contained if no additional cases surface and transaction levels hold steady. The FDA’s investigation is still in progress.
The FDA’s outbreak updates and Chipotle’s upcoming traffic report are the next checkpoints. The 1.0% transaction increase in Q2 stands out as the main operating benchmark.
Related articles: NYSE:CMG
